New Published Case Series Explores Umbilical Cord Tissue Allografts in Plantar Fascia Care
This story raises questions about governance, accountability, and American values.
a company press release, a promising case series, and the assumption that more biotech is automatically better. But the framing skips the questions patients actually have when a new “regenerative” product shows up in a clinic. An observational series is not the same as rigorous evidence, and promotional coverage can blur that line.
New Republican Times Editorial Board
PENSACOLA, Fla., Feb. 4, 2026 /PRNewswire/ -- Regenative Labs, in collaboration with Babak Baravarian, DPM, Director of Foot & Ankle Research at University Foot & Ankle Institute, today announced the publication of a new observational case series examining the use of Wharton's jelly
Original source:
Read at Pr NewswireHow We See It
New Republican Times Editorial Board
a company press release, a promising case series, and the assumption that more biotech is automatically better. But the framing skips the questions patients actually have when a new “regenerative” product shows up in a clinic.
An observational series is not the same as rigorous evidence, and promotional coverage can blur that line. If these allografts are effective, great. Yet public trust depends on clear disclosure, sober claims, and outcomes that hold up outside a handpicked setting.
Conservatives aren’t anti-innovation. We are pro rule of law, medical transparency, and fairness for patients and payers. That means tight oversight of sourcing, consent, and marketing, plus honest cost-benefit data.
The principle at stake is simple: institutions should earn confidence, not borrow it from buzzwords.
Commentary written with AI assistance by the New Republican Times Editorial Board.